Effectiveness of heterologous third and fourth dose COVID-19 vaccine schedules for SARS-CoV-2 infection during delta and omicron predominance in Thailand: a test-negative, case-control study
Authors:
- Suwat ChariyalertsakSCSuwat Chariyalertsak
- Pimpinan KhammawanPKPimpinan Khammawan
Open Access
- 29 November 2022
- journal article
- research article
- Published by Elsevier in The Lancet Regional Health - Southeast Asia
- Vol. 10, 100121
Abstract
No abstract availableKeywords
Funding Information
- National Research Council of Thailand
This publication has 21 references indexed in Scilit:
- Economic impact of COVID-19 pandemic on healthcare facilities and systems: International perspectivesBest Practice & Research Clinical Anaesthesiology, 2021
- Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trialThe Lancet, 2021
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccinationNature Medicine, 2021
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trialThe Lancet, 2021
- The Combined Effect of Vaccination and Nonpharmaceutical Public Health Interventions—Ending the COVID-19 PandemicJAMA Network Open, 2021
- Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling studyThe Lancet Infectious Diseases, 2021
- Application technology to fight the COVID-19 pandemic: Lessons learned in ThailandBiochemical and Biophysical Research Communications, 2021
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UKThe Lancet, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac – PROFISCOV: A structured summary of a study protocol for a randomised controlled trialTrials, 2020